BioScience Health Innovations, Inc.

Overview

Compare with Datacentrex, Inc., SideChannel, Inc. or TechCreate Group Ltd., or pick any stock.

• TickerBHIC on OTC¹
• IndustryServices-Computer Processing & Data Preparation¹
• HeadquartersBluffdale, Utah¹
• Incorporated inNV³
• Business address14857 South Concord Park Drive, Bluffdale, Ut 84065³
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

What it owns

What BioScience Health Innovations, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our principal place of business is 14857 South Concord Park Drive, Bluffdale, UT 84065. On December 1, 2025, we entered a 15-month rental arrangement for our office and inventory space. We believe that these facilities are adequate for our current needs. We do not own any real estate.

Item 2 of the 10-K filed Mar 30, 2026.¹²

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorDARREN LOPEZ named Jun 17, 2024¹³

Former names

• Nowtransit IncNov 4, 2019 to Mar 13, 2025³

Timeline

1. Apr 2, 20268-K Executive or director change¹⁴
2. Oct 16, 20258-K Bylaws or fiscal year changed; Shareholder vote¹⁵
3. Mar 17, 20258-K Bylaws or fiscal year changed¹⁶
4. Jun 25, 20248-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares¹⁷
5. May 22, 20248-K Change of auditor¹⁸
6. Mar 23, 20238-K Executive or director change¹⁹
7. Mar 16, 20238-K Completed an acquisition or sale; Unregistered sale of shares; Executive or director change²⁰
8. Feb 17, 20238-K Entered a material agreement²¹
9. Nov 29, 20228-K Entered a material agreement²²

Filings

37 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 9 major events, 2 private raises, 5 other. The latest 20:

1. Aug 7, 202610-Q BIOSCIENCE HEALTH INNOVATIONS INC. - FORM 10-Q SEC FILING EDGAR
2. Jul 9, 2026QUALIF EDGAR
3. Jul 6, 20261-A POS EDGAR
4. May 11, 202610-Q EDGAR
5. Apr 2, 20268-K EDGAR
6. Mar 30, 202610-K EDGAR
7. Dec 4, 2025QUALIF EDGAR
8. Dec 2, 2025CORRESP EDGAR
9. Nov 25, 20251-A EDGAR
10. Oct 27, 202510-Q EDGAR
11. Oct 16, 20258-K EDGAR
12. Aug 7, 202510-Q EDGAR
13. May 8, 202510-Q EDGAR
14. Mar 17, 20258-K EDGAR
15. Mar 13, 202510-K EDGAR
16. Oct 28, 202410-Q EDGAR
17. Jul 30, 202410-Q EDGAR
18. Jun 25, 20248-K/A EDGAR
19. Jun 17, 2024D/A EDGAR
20. May 22, 20248-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 22, 2023Raised $420,000 in a private offering of equity¹³ Form D: $1 million offered in all Form D

SEC filer profile

How BioScience Health Innovations, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARBioScience Health Innovations, Inc.¹
• CIK0001784440
• Employer ID (EIN)98-1498782¹²
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company¹²
• Incorporated inNevada¹²
• Fiscal year endsDecember 31¹
• Industry code (SIC)7374 Services-Computer Processing & Data Preparation¹
• SEC reviewing officeOffice of Technology, Division of Corporation Finance¹
• Business address14857 South Concord Park Drive, Bluffdale, UT 84065¹
• Phone801-949-0791¹
• Shares outstanding11,752,329 as of Aug 6, 2026⁵
• Public float$43.9M as of Jun 30, 2025¹²
• AuditorMac Accounting Group & CPAs, LLP, Midvale, Utah PCAOB ID 6258; no auditor attestation of internal control over financial reporting¹²
• On EDGAR sinceNov 4, 2019¹
• Filings53 in all: 10-Q (22), 8-K (9), 10-K (6), CORRESP (3), QUALIF (2), S-1/A (2), UPLOAD (2), 1-A (1)¹
  All 14 form types

  1-A POS (1), 8-K/A (1), D (1), D/A (1), EFFECT (1), S-1 (1)

• Latest filingsAnnual report (10-K) Mar 30, 2026
  Quarterly report (10-Q) Aug 7, 2026
  Latest 8-K (8-K) Apr 2, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).¹²

Risk factors and legal proceedings

The risks BioScience Health Innovations, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 10 risks under these headings, as written.¹²

• Because we have limited capital, we may need to raise additional capital in the future by issuing debt or equity securities, the terms of which may dilute our current investors and/or reduce or limit their liquidation or other rights.
• We may be unable to obtain necessary financing if and when required.
• Risks Related to Our Common Stock
• Due to factors beyond our control, our stock price may be volatile.
• Because trading in our common stock is so limited, investors who purchase our common stock may depress the market if they sell common stock.
• The market price of our common stock may decline if a substantial number of shares of our common stock are sold at once or in large blocks.
• Future issuances of our common stock could dilute the interests of our existing shareholders, particularly in connection with an acquisition and any resulting financing.
• Because our common stock is subject to the “penny stock” rules, brokers cannot generally solicit the purchase of our common stock, which adversely affects its liquidity and market price.
• Because of FINRA sales practice requirements which affect broker-dealers, the market price for our common stock will be adversely affected.
• Due to changes to Rule 15c2-11 under the Securities Exchange Act of 1934, our common stock may become subject to limitations or reductions on stock price, liquidity or volume.
• Because we may issue preferred stock without the approval of our shareholders and have other anti-takeover defenses, it may be more difficult for a third-party to acquire us and could depress our stock price.

Legal proceedings

We are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us that would have a material adverse effect on us or our business.

The opening of Item 3, Legal Proceedings.¹²